Phase 2 Study of Plamotamab Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in Relapsed or Refractory (R/R) Diffuse Large-cell B-cell Lymphoma (DLBCL)

Stopped The study has been terminated early by the sponsor due to business decision.

Conditions

• Diffuse Large-cell B-cell Lymphoma

Interventions

• BIOLOGICAL: Plamotamab
• BIOLOGICAL: Tafasitamab
• DRUG: Lenalidomide

Sponsor

Xencor, Inc.